2024
Medicare Coverage and Patient Out-of-Pocket Costs for Cardiovascular-Kidney-Metabolic Medications
Young G, Bansal K, Riello R, Clark K, Dhruva S, Faridi K, Desai N. Medicare Coverage and Patient Out-of-Pocket Costs for Cardiovascular-Kidney-Metabolic Medications. JAMA Network Open 2024, 7: e2412437. PMID: 38771578, PMCID: PMC11109768, DOI: 10.1001/jamanetworkopen.2024.12437.Peer-Reviewed Original Research
2023
Translating Evidence-based Approaches into optimal Care for individuals at High-risk of ASCVD: Pilot testing of case-based e-learning modules and design of the TEACH-ASCVD study
Clegg K, Schubert T, Block R, Burke F, Desai N, Greenfield R, Karalis D, Kris-Etherton P, McNeal C, Nahrwold R, Peña J, Plakogiannis R, Wong N, Jones L. Translating Evidence-based Approaches into optimal Care for individuals at High-risk of ASCVD: Pilot testing of case-based e-learning modules and design of the TEACH-ASCVD study. Journal Of Clinical Lipidology 2023, 17: 592-601. PMID: 37550150, DOI: 10.1016/j.jacl.2023.07.007.Peer-Reviewed Original ResearchConceptsAtherosclerotic cardiovascular diseaseEvidence-based guidelinesASCVD patientsDetailed patient historyCause of deathClinical best practicesBetter patient careEvidence-based managementU.S. health systemEvidence-based approachOptimal careCardiovascular diseasePatient historyDiagnostic criteriaClinician groupsField of lipidologyPatient careHealth systemCliniciansPatientsCarePilot testingGuidelinesFocus groupsElicit feedbackFrequency and clinicoeconomic impact of delays to definitive diagnosis of obstructive hypertrophic cardiomyopathy in the United States
Naidu S, Sutton M, Gao W, Fine J, Xie J, Desai N, Owens A. Frequency and clinicoeconomic impact of delays to definitive diagnosis of obstructive hypertrophic cardiomyopathy in the United States. Journal Of Medical Economics 2023, 26: 682-690. PMID: 37170479, DOI: 10.1080/13696998.2023.2208966.Peer-Reviewed Original ResearchConceptsObstructive hypertrophic cardiomyopathyDefinitive diagnosisHypertrophic cardiomyopathyHCM diagnosisMedicare Supplemental databasesIBM MarketScan CommercialEmergency room visitsAdministrative claims dataMisclassification of patientsEligible patientsMarketScan CommercialMost patientsRoom visitsAlternative diagnosesPotential misdiagnosesCardiovascular conditionsInappropriate treatmentDatabase studyClaims dataHealthcare costsDiagnostic journeyPatientsEconomic burdenCurrent studyDiagnostic historyTrends in Spending and Claims for P2Y12 Inhibitors by Medicare and Medicaid From 2015 to 2020
Essa M, Ross J, Dhruva S, Desai N, Yeh R, Faridi K. Trends in Spending and Claims for P2Y12 Inhibitors by Medicare and Medicaid From 2015 to 2020. Journal Of The American Heart Association 2023, 12: e028869. PMID: 37042289, PMCID: PMC10227267, DOI: 10.1161/jaha.122.028869.Peer-Reviewed Original ResearchPatterns of Care and Outcomes of Ambulatory Endovascular Interventions in Lower Extremity Peripheral Arterial Disease
Chaturvedi A, Castro-Dominguez Y, Gertz Z, Lawson B, Chandrika P, Gupta R, Milioglou I, Sung J, Desai N, Vetrovec G, Kochar A, Guha A. Patterns of Care and Outcomes of Ambulatory Endovascular Interventions in Lower Extremity Peripheral Arterial Disease. The American Journal Of Cardiology 2023, 194: 17-26. PMID: 36924641, DOI: 10.1016/j.amjcard.2023.02.006.Peer-Reviewed Original ResearchConceptsPatterns of careEndovascular interventionCardiovascular eventsLower Extremity Peripheral Arterial DiseaseLower extremity endovascular interventionsChronic kidney diseasePeripheral arterial diseasePeripheral artery diseasePrimary treatment modalityIschemic heart diseaseNon-Medicare insuranceUrban teaching facilityDisease refractoryUncontrolled hypertensionMost patientsArtery diseaseHeart failureArterial diseaseStudy cohortKidney diseaseMean ageNoninvasive managementTreatment modalitiesHeart diseaseFemale genderClinical Outcomes, Resource Utilization, and Treatment Over the Disease Course of Symptomatic Obstructive Hypertrophic Cardiomyopathy in the United States
Desai N, Sutton M, Xie J, Fine J, Gao W, Owens A, Naidu S. Clinical Outcomes, Resource Utilization, and Treatment Over the Disease Course of Symptomatic Obstructive Hypertrophic Cardiomyopathy in the United States. The American Journal Of Cardiology 2023, 192: 16-23. PMID: 36709525, DOI: 10.1016/j.amjcard.2022.12.030.Peer-Reviewed Original ResearchConceptsObstructive hypertrophic cardiomyopathyHypertrophic cardiomyopathyIndex dateCardiovascular eventsIncidence rateSymptomatic obstructive hypertrophic cardiomyopathyAtrial fibrillation/flutterCommon cardiovascular eventMonths continuous eligibilityHealthcare resource utilizationMedicare Supplemental databasesIBM MarketScan CommercialEligible patientsDiagnosis dateMarketScan CommercialClinical outcomesContinuous eligibilityTreatment optionsCumulative riskPatientsResource utilizationPharmacotherapyCardiomyopathyDisease
2022
Pragmatic trial of messaging to providers about treatment of acute heart failure: The PROMPT-AHF trial
Ghazi L, O'Connor K, Yamamoto Y, Fuery M, Sen S, Samsky M, Riello R, Huang J, Olufade T, McDermott J, Inzucchi S, Velazquez E, Wilson F, Desai N, Ahmad T. Pragmatic trial of messaging to providers about treatment of acute heart failure: The PROMPT-AHF trial. American Heart Journal 2022, 257: 111-119. PMID: 36493842, DOI: 10.1016/j.ahj.2022.12.002.Peer-Reviewed Original ResearchConceptsGuideline-directed medical therapyAcute heart failureHeart failurePragmatic trialElectronic health recordsSubstantial health care costsBest practice advisoryReduced ejection fractionUsual care armHealth recordsTime of dischargeEvidence-based careHealth care costsClinical decision support systemAHF patientsCare armEligible patientsHF hospitalizationInpatient initiationCardiovascular deathMedication classesEjection fractionMedical therapyPrimary outcomePractice advisoryAssessment of Market-Level Information on Quality Using Hospital Care Compare
Oddleifson D, Xu X, Ross J, Spatz E, Desai N. Assessment of Market-Level Information on Quality Using Hospital Care Compare. Journal Of General Internal Medicine 2022, 38: 1581-1583. PMID: 36443632, PMCID: PMC10160280, DOI: 10.1007/s11606-022-07965-9.Peer-Reviewed Original ResearchMedicare Coverage and Out-of-Pocket Costs of Quadruple Drug Therapy for Heart Failure
Faridi K, Dayoub E, Ross J, Dhruva S, Ahmad T, Desai N. Medicare Coverage and Out-of-Pocket Costs of Quadruple Drug Therapy for Heart Failure. Journal Of The American College Of Cardiology 2022, 79: 2516-2525. PMID: 35738713, DOI: 10.1016/j.jacc.2022.04.031.Peer-Reviewed Original ResearchConceptsSodium-glucose cotransporter 2 inhibitorsAngiotensin receptor neprilysin inhibitorQuadruple therapyOOP costsMedicare coveragePocket costsAngiotensin-converting enzyme inhibitorPrior authorizationAngiotensin receptor blockersQuadruple drug therapyCotransporter 2 inhibitorsMineralocorticoid receptor antagonistsReduced ejection fractionDrug plansReceptor blockersEjection fractionHeart failureDrug therapyReceptor antagonistPrescription drug plansMedicare patientsEnzyme inhibitorsTherapyRegimensMedication prices
2021
Sex Differences in Ablation Strategy, Lesion Sets, and Complications of Catheter Ablation for Atrial Fibrillation: An Analysis From the GWTG-AFIB Registry
Yunus F, Perino A, Holmes D, Matsouaka R, Curtis A, Ellenbogen K, Frankel D, Knight B, Russo A, Lewis W, Piccini J, Turakhia M, Day J, Desai N, Feld G, Fonarow G, Hurwitz J, Joglar J, Sheth K, Sidhu M. Sex Differences in Ablation Strategy, Lesion Sets, and Complications of Catheter Ablation for Atrial Fibrillation: An Analysis From the GWTG-AFIB Registry. Circulation Arrhythmia And Electrophysiology 2021, 14: e009790. PMID: 34719235, DOI: 10.1161/circep.121.009790.Peer-Reviewed Original ResearchConceptsAblation strategyNonparoxysmal AFLesion setsPatient sexInitial AF ablation procedureAdvanced atrial diseaseAtrial linear ablationNonpulmonary vein triggersQuality improvement registryAF ablation proceduresAtrial fibrillation ablationOptimal ablation strategyAF ablation strategiesAF ablationPatient demographicsCatheter ablationFibrillation ablationMultivariable analysisAtrial diseaseAtrial fibrillationLinear ablationAF typeAblation proceduresComplicationsPatientsPrevention of atherosclerotic cardiovascular disease in South Asians in the US: A clinical perspective from the National Lipid Association
Kalra D, Vijayaraghavan K, Sikand G, Desai N, Joshi P, Mehta A, Karmally W, Vani A, Sitafalwalla S, Puri R, Duell P, Brown A. Prevention of atherosclerotic cardiovascular disease in South Asians in the US: A clinical perspective from the National Lipid Association. Journal Of Clinical Lipidology 2021, 15: 402-422. PMID: 33846108, DOI: 10.1016/j.jacl.2021.03.007.Peer-Reviewed Original ResearchConceptsAtherosclerotic cardiovascular diseaseSouth AsiansLack of physical exerciseRates of atherosclerotic cardiovascular diseaseCholesterol treatment guidelinesCardiovascular diseasePrevention of atherosclerotic cardiovascular diseaseNational Lipid AssociationPrevalence of atherosclerotic cardiovascular diseaseAge-matched peoplePractical prevention strategiesHealthcare providersPhysical exerciseDietary advicePrevention strategiesDietary factorsEarly screeningRisk enhancementTreatment guidelinesConsensus documentVisceral adiposityExpert consensus documentAsiansClinical perspectiveLipid association